FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 579 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR Prescribing Exercise as Cancer Treatment: A Conversation with Dr. Kathryn Schmitz November 12, 2019 Withdrawal of Application to Change the Marketing Authorisation for Atezolizumab February 4, 2021 New Class of Compounds Rewires Cancer Cells to Self-Destruct August 29, 2023 ‘Scandinavian quality and Singaporean efficiency’: what the autumn statement means for... November 17, 2022 Load more HOT NEWS Study Examines Whether Blood Test Can Identify Early Cancers Common anti-inflammatory drug could boost cancer immunotherapy Significant Intracranial Efficacy and Survival Benefits of Osimertinib in Patients with... Cancer Drug Lynparza Found to Lower Risk of Death and Recurrence...
